Moderna Shares Spike After Cancer Therapy Trial Announcement
The personalised mRNA shot was paired with Keytruda and cut recurrence and spread risk in more than 1,000 patients, companies said.
6 Articles
6 Articles
Moderna Shares Spike After Cancer Therapy Trial Announcement
This is a web version of The Lever’s daily email newsletter. 🔥 ICYMI in The Lever: This Senate candidate doesn’t care if AT&T spies on you.👇 Further down in this newsletter:Are taxpayers getting shortchanged by Moderna’s cancer vaccine?The Justice Department’s hot take machine.Big Oil is asking the Supreme Court for a shield. STORIES TO GO In a hurry? These are some of the top stories in the country.🏦 A global bond sell-off has ignited fears …
Moderna and MSD announced the successful completion of Phase 3 clinical trials for Intismeran, a personalized cancer vaccine utilizing mRNA technology. The vaccine demonstrated efficacy in preventing recurrence and metastasis when administered in combination with Keytruda to melanoma patients. The company plans to expand research to various cancer types, including lung cancer, with the goal of launching the product in 2027.
The pharmaceutical companies Moderna and MSD have unveiled trial results with a cancer vaccine, which, according to a professor, promises good things for all of humanity's fight against the disease.
Coverage Details
Bias Distribution
- 80% of the sources lean Left
Factuality
To view factuality data please Upgrade to Premium
